Cited by 46Amino Acid Enzymes and MetabolismCancer, Hypoxia, and MetabolismBiochemical and Molecular Research

Differential 3-bromopyruvate inhibition of cytosolic and mitochondrial human serine hydroxymethyltransferase isoforms, key enzymes in cancer metabolic reprogramming

Paiardini, Alessandro, Tramonti, Angela, Schirch, Doug, Guiducci, Giulia, di Salvo, Martino Luigi, Fiascarelli, Alessio, Giorgi, Alessandra, Maras, Bruno +2 more·2016·Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

Abstract

The cytosolic and mitochondrial isoforms of serine hydroxymethyltransferase (SHMT1 and SHMT2, respectively) are well-recognized targets of cancer research, since their activity is critical for purine and pyrimidine biosynthesis and because of their prominent role in the metabolic reprogramming of cancer cells. Here we show that 3-bromopyruvate (3BP), a potent novel anti-tumour agent believed to function primarily by blocking energy metabolism, differentially inactivates human SHMT1 and SHMT2. SHMT1 is completely inhibited by 3BP, whereas SHMT2 retains a significant fraction of activity. Site directed mutagenesis experiments on SHMT1 demonstrate that selective inhibition relies on the presence of a cysteine residue at the active site of SHMT1 (Cys204) that is absent in SHMT2. Our results show that 3BP binds to SHMT1 active site, forming an enzyme-3BP complex, before reacting with Cys204. The physiological substrate l-serine is still able to bind at the active site of the inhibited enzyme, although catalysis does not occur. Modelling studies suggest that alkylation of Cys204 prevents a productive binding of l-serine, hampering interaction between substrate and Arg402. Conversely, the partial inactivation of SHMT2 takes place without the formation of a 3BP-enzyme complex. The introduction of a cysteine residue in the active site of SHMT2 by site directed mutagenesis (A206C mutation), at a location corresponding to that of Cys204 in SHMT1, yields an enzyme that forms a 3BP-enzyme complex and is completely inactivated. This work sets the basis for the development of selective SHMT1 inhibitors that target Cys204, starting from the structure and reactivity of 3BP.

Integrity signals

Registry

Crossref · 10.1016/j.bbapap.2016.08.010

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Paiardini, A., Tramonti, A., Schirch, D., Guiducci, G., di Salvo, M. L., Fiascarelli, A., Giorgi, A., Maras, B., Cutruzzolà, F., & Contestabile, R.
Affiliations
  • Sapienza University of Rome (IT)
  • Institute of Molecular Biology and Pathology (IT)
Corresponding author
  • Cutruzzolà, Francesca
  • Contestabile, Roberto
Venue
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Publisher
Elsevier BV
Published
2016-11
Volume
1864
Issue
11
Pages
1506-1517
ISSN
1570-9639 (ISSN-L)
OpenAlex
W2507335544
Cited by
44
References
60
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 6
FWCI
3.76
Type
journal article
Language
en
Open access
closed
Locations
  • Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
Funders
  • Regione Lazio (FILAS-RU-2014–1020)
  • Sapienza University of Rome (2015-C26A155WEE, C26A149EC4)
  • Associazione Italiana Ricerca sul Cancro (AIRC-IG2015, 16720)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
3-bromopyruvate, serine hydroxymethyltransferase, SHMT1, SHMT2, enzyme inhibition, active site cysteine, selective inhibitors, tumor metabolic reprogramming, pyrimidine synthesis, purine biosynthesis, alkylation, anticancer agents
MeSH terms
Protein Domains, Amino Acid Sequence, Antineoplastic Agents, Cloning, Molecular, Cysteine, Cytosol, Escherichia coli, Humans, Kinetics, Mitochondria, Protein Binding, Pyruvates, Recombinant Proteins, Serine, Glycine Hydroxymethyltransferase, Structure-Activity Relationship, Gene Expression, Mutagenesis, Site-Directed, Protein Structure, Secondary, Catalytic Domain, Enzyme Assays, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review